Oct 2026
A randomized phase III study optimizing adjuvant osimertinib for resected EGFR-mutant stage II-III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01).
Ken Onodera, Yoshinori Okada, Y. Kudo et al.
· Japanese Journal of Clinical... · 0 citations